Key Takeaways
- Humana reported Q1 adjusted EPS of $10.31, surpassing analyst consensus of $10.19–$10.20
- Shares tumbled as much as 7.4% during premarket hours despite exceeding earnings projections
- Annual adjusted EPS guidance remained at $9, while reported earnings outlook declined to $8.36 from $8.89
- Declining Medicare Advantage Star Ratings for 2026 are pressuring bonus payments and overall profitability
- Management highlighted an expanding disconnect between healthcare expenditures and government reimbursement rates
Humana delivered first-quarter results that topped analyst expectations on Wednesday, yet the market response was decidedly negative. Shares plunged as much as 7.4% in premarket activity after the healthcare insurance giant maintained its yearly profit projections while competitors boosted their forecasts.
The company posted adjusted earnings of $10.31 per share, exceeding Wall Street’s consensus estimate range of approximately $10.19–$10.20. Total revenue climbed to $39.65 billion from $32.11 billion in the prior-year period, also surpassing the projected $39.37 billion.
Despite these solid numbers, investor confidence remained shaken.
Morningstar’s equity analyst Julie Utterback suggested that market participants had anticipated Humana would increase its forward-looking estimates following such a robust quarterly performance. Instead, the company left its targets untouched.
Management reaffirmed its full-year adjusted earnings projection of at least $9 per share. However, on a GAAP basis, the forecast was actually lowered — now targeting at least $8.36 per share compared to the prior estimate of at least $8.89.
The downward revision accounts for expenses associated with a comprehensive multi-year restructuring initiative, encompassing severance packages, asset write-downs, and external advisory fees.
Medicare Star Rating Challenges Impact Profitability
A critical factor driving investor concern is Humana’s diminished Medicare Advantage Star Ratings for the 2026 performance year. These government-issued quality ratings, ranging from one to five stars, directly determine eligibility for federal bonus payments. Reduced ratings translate to smaller bonus revenues.
Management has been signaling this obstacle for several quarters. First-quarter net income registered at $9.83 per share, a decline from $10.30 in the comparable period last year — illustrating the tangible impact of this ratings pressure.
Chief Executive Jim Rechtin indicated that healthcare utilization patterns and associated costs tracked in line with internal projections. However, he acknowledged that the differential between the company’s medical expenditures and federal reimbursement levels has widened year-over-year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Medical Loss Ratio Shows Positive Trend
Amid the challenges, one encouraging metric emerged: Humana’s insurance division reported a benefit ratio of 89.4% for the first quarter. This figure represents the percentage of premium revenue allocated to medical claims and came in better than the company’s internal forecast of just under 90%, while also beating the Street’s expectation of 89.7%.
A lower benefit ratio is favorable for insurers, and readings below 90% typically indicate effective cost management.
Looking to the second quarter, Humana projects this metric will increase to slightly above 91%, suggesting emerging cost headwinds in the coming months.
The company also observed that aggregate medical and pharmacy expense trends are performing modestly better than anticipated, which Cantor Fitzgerald analyst Sarah James identified as among the limited positive elements in the quarterly report.
Nevertheless, James raised caution flags. “HUM has several signals that the back-half of the year could be difficult to manage,” she stated, characterizing the premarket sell-off as “a warning sign.”
Humana indicated it will modify plan benefits where necessary to preserve target margin levels. Earlier this month, the federal government announced Medicare Advantage payment rates would increase by an average of 2.48% for the 2027 calendar year.
Shares were trading down approximately 2% in premarket activity after the initial 7.4% decline.
